柯萨奇病毒A组16型的研究进展

doi:10.3969/j.issn.1674-490X.2020.06.002

摘要/Abstract

摘要： 柯萨奇病毒A组16型(Coxsackievirus A group 16 strain,CA16)感染在中国很常见,CA16在流行过程中不断发生变异,其致病性与肠道病毒71型有明显差异。CA16可诱导产生多种微小核糖核酸,影响炎性信号通路的传导,导致病理损害的发生。目前已成功建立了小鼠、树鼩、猕猴CA16感染模型,可用于评估抗CA16药物和疫苗效果。检测方面,多重实时逆转录聚合酶链反应可针对手足口病进行高灵敏度检测和快速分型,胶体金免疫层析法可用于现场的快速诊断。多种单价、多价的CA16疫苗在动物实验中诱导出有效的免疫。

关键词: 柯萨奇病毒A组16型, 手足口病, 致病性, 动物模型

Abstract: Coxsackievirus A group 16 strain(CA16)infection is very common in China. CA16 constantly mutated in the epidemic process, and its pathogenicity is significantly different from enterovirus 71(EV71). CA16 can induce a variety of microRNAs(miRNAs)and affect the transmission of inflammatory signaling pathways, leading to pathological damage. At present, CA16 infection models in mice, tree shrews and macaques have been successfully established, which can be used to evaluate the effect of anti CA16 drugs and vaccines. In terms of detection, multiplex real-time RT-PCR can be used for high-sensitivity detection and rapid typing of HFMD, and colloidal gold immunochromatographic assays can be used for rapid diagnosis. A variety of monovalent and multivalent CA16 vaccines can induce effective immunity in animal experiments.

Key words: Coxsackievirus A group 16 strain, hand, foot and mouth disease, pathogenicity, animal model

中图分类号:

R512.5

马士恒,李明. 柯萨奇病毒A组16型的研究进展[J]. 医学研究与教育, 2020, 37(6): 7-13.

参考文献

[1] 孙立梅, 吴崧霖, 潭小华, 等. 广东省2012—2016年柯萨奇病毒A组16型感染手足口病病例流行特征分析[J].中华流行病学杂志, 2018, 39(3): 342-346. DOI: 10.3760/cma.j.issn.0254-6450.2018.03.018.
[2] 刘艳艳, 简千棋, 马丽波, 等. 2013—2018年昆明市重症手足口病实验室监测结果分析[J]. 现代预防医学, 2020, 47(2): 314-316.
[3] 张海艳, 许宝麟, 黄辉, 等. 2013—2016年北京市东城区手足口病流行病学特征[J]. 职业与健康, 2018, 34(6): 808-810. DOI: 10.13329/j.cnki.zyyjk.2018.0223.
[4] 张萌, 段亚丽, 王巍, 等. 北京及其周边地区儿童手足口病病原学监测及流行病学分析(2017—2018年)[J].国际流行病学传染病学杂志, 2020, 47(1): 21-24. DOI: 10.3760/cma.j.issn.1673-4149.2020.01.005.
[5] 朱宝增, 赵文娜, 刘莹莹, 等. 河北省2008-2017年手足口病流行和病原特征分析[J].中华疾病控制杂志, 2019,23(3): 356-359. DOI: 10.16462/j.cnki.zhjbkz.2019.03.023.
[6] 姚学君, 李家学, 李靖欣, 等. 江苏某农村地区柯萨奇病毒A组16型感染所致疾病负担研究[J].江苏预防医学, 2018, 29(4): 368-370. DOI: 10.13668/j.issn.1006-9070.2018.04.002.
[7] RAO D C, NAIDU J R, MAIYA P P, et al. Large-scale HFMD epidemics caused by Coxsackievirus A16 in Bangalore, India during 2013 and 2015[J]. Infect Genet Evol, 2017, 55: 228-235. DOI: 10.1016/j.meegid.2017.08.030.
[8] ZHAO K, HAN X, WANG G, et al. Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China[J]. Emerg Infect Dis, 2011, 17(8): 1537-1540. DOI: 10.3201/eid1708.101719.
[9] 耿海杰,任丽萍,封永建,等.西宁市2017—2018年柯萨奇A16型肠道病毒VP1基因分子特征分析[J].中华实验和临床病毒学杂志,2019,33(5): 482-484. DOI: 10.3760/cma.j.issn.1003-9279.2019.05.008.
[10] 王杨, 李祎, 彭传梅, 等. 手足口病柯萨奇病毒A组16型VP1基因遗传变异[J]. 中华传染病杂志, 2019, 37(3): 163-166. DOI: 10.3760/cma.j.issn.1000-6680.2019.03.007.
[11] 姚相杰, 王伟琪, 陈龙, 等. 2016—2017年深圳地区柯萨奇病毒A16型分子特征分析[J]. 中华微生物学和免疫学杂志, 2019, 39(9): 652-656. DOI: 10.3760/cma.j.issn.0254-5101.2019.09.002.
[12] 刘俊, 杨雅林, 张曦. 柯萨奇病毒A组16型与肠道病毒71型致手足口病临床特点比较[J]. 中国药物与临床, 2019, 19(13): 2222-2224. DOI: 10.11655/zgywylc2019.13.036.
[13] YANG J H, YANG C F, GUO N N, et al. Type I interferons triggered through the toll-like receptor 3-TRIF pathway control coxsackievirus A16 infection in young mice[J]. J Virol, 2015, 89(21): 10860-10867. DOI: 10.1128/jvi.01627-15.
[14] 屈晓婷. CA6阳性与EV71、CA16阳性手足口病患儿临床特征分析[J]. 中国妇幼健康研究, 2017, 28(10): 1226-1228. DOI: 10.3969/j.issn.1673-5293.2017.10.021.
[15] RUI Y J, SU J M, WANG H, et al. Disruption of MDA5-mediated innate immune responses by the 3C proteins of coxsackievirus A16, coxsackievirus A6, and Enterovirus D68[J]. J Virol, 2017, 91(13): 1-21. DOI: 10.1128/jvi.00546-17.
[16] BUSCH A, EKEN S M, MAEGDEFESSEL L. Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease[J]. Ann Transl Med, 2016, 4(12): 236. DOI: 10.21037/atm.2016.06.06.
[17] HU Y J, SONG J, LIU L D, et al. Comparison analysis of microRNAs in response to EV71 and CA16 infection in human bronchial epithelial cells by high-throughput sequencing to reveal differential infective mechanisms[J]. Virus Res, 2017, 228: 90-101. DOI: 10.1016/j.virusres.2016.11.024.
[18] SONG J, HU Y J, HU Y G, et al. Global gene expression analysis of peripheral blood mononuclear cells in rhesus monkey infants with CA16 infection-induced HFMD[J]. Virus Res, 2016, 214: 1-10. DOI: 10.1016/j.virusres.2016.01.002.
[19] LIU Q W, SHI J P, HUANG X L, et al. A murine model of coxsackievirus A16 infection for anti-viral evaluation[J]. Antivir Res, 2014, 105: 26-31. DOI: 10.1016/j.antiviral.2014.02.015.
[20] LI J P, LIAO Y, ZHANG Y, et al. Experimental infection of tree shrews(Tupaia belangeri)with Coxsackie virus A16[J]. Zoological Res, 2014, 35(6): 485-491. DOI: 10.13918/j.issn.2095-8137.2014.6.485.
[21] WANG J J, ZHANG Y, ZHANG X L, et al. Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques[J]. Virology, 2017, 500: 198-208. DOI: 10.1016/j.virol.2016.10.031.
[22] PUENPA J, SUWANNAKARN K, CHANSAENROJ J, et al. Development of single-step multiplex real-time RT-PCR assays for rapid diagnosis of Enterovirus 71, coxsackievirus A6, and A16 in patients with hand, foot, and mouth disease[J]. J Virol Methods, 2017, 248: 92-99. DOI: 10.1016/j.jviromet.2017.06.013.
[23] ZHANG J, WENG Z X, DU H L, et al. Development and evaluation of rapid point-of-care tests for detection of Enterovirus 71 and Coxsackievirus A16 specific immunoglublin M antibodies[J]. J Virol Methods, 2016, 231: 44-47. DOI: 10.1016/j.jviromet.2016.01.015.
[24] 郑惠文, 候东佩, 李嘉祺, 等. 基于重组荧光病毒的流式细胞术检测抗CV-A16中和抗体的研究[J]. 病毒学报, 2020, 36(3): 385-393. DOI: 10.13242/j.cnki.bingduxuebao.003697.
[25] WANG J J, QI S D, ZHANG X L, et al. Coxsackievirus A 16 infection does not interfere with the specific immune response induced by an Enterovirus 71 inactivated vaccine in rhesus monkeys[J]. Vaccine, 2014, 32(35): 4436-4442. DOI: 10.1016/j.vaccine.2014.06.062.
[26] YANG L S, LIU Y J, LI S X, et al. A novel inactivated Enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice[J]. Vaccine, 2016, 34(48): 5938-5945. DOI: 10.1016/j.vaccine.2016.10.018.
[27] LYU K, HE Y L, LI H Y, et al. Crystal structures of yeast-produced Enterovirus 71 and Enterovirus 71/coxsackievirus A16 chimeric virus-like particles provide the structural basis for novel vaccine design against hand-foot-and-mouth disease[J]. J Virol, 2015, 89(12): 6196-6208. DOI: 10.1128/jvi.00422-15.
[28] ZHANG C, LIU Q W, KU Z Q, et al. Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice[J]. Antivir Res, 2016, 129: 47-51. DOI: 10.1016/j.antiviral.2016.02.011.
[29] 张浩然, 姜莉, 杨二霞, 等. 不同佐剂对柯萨奇病毒A组16型灭活疫苗诱导小鼠体液免疫应答的影响[J]. 药物评价研究, 2020, 43(5): 829-834. DOI: 10.7501/j.issn.1674-6376.2020.05.006.
[30] LIM H, IN H J, LEE J A, et al. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease[J]. Vaccine, 2018, 36(24): 3445-3452. DOI: 10.1016/j.vaccine.2018.05.005.